Sotyktu floundering

Quote




Not true. I’m a consultant with BMS, Commercial US Dermatogy will remain untouched and will continue to increase access. ELT is looking for Derm to continue to grow through 2025 and with PsA.
 



anonymous said:
Not true. I’m a consultant with BMS, Commercial US Dermatogy will remain untouched and will continue to increase access. ELT is looking for Derm to continue to grow through 2025 and with PsA.
Click to expand...
I agree. Derm is safe. They need the sales force for the launch. Now that the Orencia sales team is back they will show Dermatology how to really sell a product. I can guarantee the Rheum reps will out perform the Derm reps with this PSA launch.
 



anonymous said:
I agree. Derm is safe. They need the sales force for the launch. Now that the Orencia sales team is back they will show Dermatology how to really sell a product. I can guarantee the Rheum reps will out perform the Derm reps with this PSA launch.
Click to expand...
WHY ON GOD'S GOOD GREEN EARTH WOULD A RHEUMATOLOGIST PRESCRIBE SOTYKTU FOR PSA WHEN THEY HAVE 47 BETTER OPTIONS FOR PSA?
 









Apremilast gets 87% of its volume from dermatology, 7% from rheumatology and 6% from other.

Rheums have dozens of better options, even orals ones, that both apremilast and deucra.

Still, almost anyone will be better than our derm sales force. Clown show.
 



anonymous said:
Apremilast gets 87% of its volume from dermatology, 7% from rheumatology and 6% from other.

Rheums have dozens of better options, even orals ones, that both apremilast and deucra.

Still, almost anyone will be better than our derm sales force. Clown show.
Click to expand...
Actually, you have it all wrong. The sales force will prove to be the only reason we succeed as it is surely not going to be consistency in hiring strong leadership, competent ELT, accurate forecasting, understanding access or formularies (insurance, hospital, or office) or Rx pull-through.
 



anonymous said:
Actually, you have it all wrong. The sales force will prove to be the only reason we succeed as it is surely not going to be consistency in hiring strong leadership, competent ELT, accurate forecasting, understanding access or formularies (insurance, hospital, or office) or Rx pull-through.
Click to expand...
Right, because psoriasis has sold like hotcakes......
 



anonymous said:
Sotyku is the leading oral in share in Dermatology, and in primary care, Orezla is leading.

BMS pays only for symphony data which includes about 40% of total Rxs. If you want to know how you are doing, ask a rep from another Derm company. I just came here from another Derm company and Sotyktu scripts are not reporting here. Why doesn’t anyone wanting to fix the problem?
Click to expand...
I came from another company as well and they only paid for the lowest level of data and many scripts went to other territories because they couldn’t be tracked to the physician or physician zip. So frustrating it’s the same here
 



anonymous said:
I came from another company as well and they only paid for the lowest level of data and many scripts went to other territories because they couldn’t be tracked to the physician or physician zip. So frustrating it’s the same here
Click to expand...
Unfortunately they don't take you seriously when you show them that there is a data missing. I witnessed a teammate present the missing data to the manager and regional. She was targeted. The manager went after her. In the end she was right about the missing data, but he didn't like to be wrong. I would keep a low profile and not mention a word about missing data.
 



anonymous said:
Unfortunately they don't take you seriously when you show them that there is a data missing. I witnessed a teammate present the missing data to the manager and regional. She was targeted. The manager went after her. In the end she was right about the missing data, but he didn't like to be wrong. I would keep a low profile and not mention a word about missing data.
Click to expand...
I meant 'missing data."
 



It is the same at every company. These large pharmaceutical companies cheat their sales reps constantly. However, the C-suite finds a way to collect data so that they can receive their bonus!
 






anonymous said:
Maybe because it is safer than a JAK and could be used as an add on therapy when treating PSA
Click to expand...
Zero data, anywhere, that it's "safer" than a JAK. Show me the head to head trials?

That's why you guys lost it pre-launch when your "medical" people were running around saying it's safer than apremilast. It might not have the nuisance side effects, but it is no safer.

Face it, you guys blew it. We are waiting for Lilly, JNJ, and Takeda orals to replace apremilast.
 



anonymous said:
Zero data, anywhere, that it's "safer" than a JAK. Show me the head to head trials?

That's why you guys lost it pre-launch when your "medical" people were running around saying it's safer than apremilast. It might not have the nuisance side effects, but it is no safer.

Face it, you guys blew it. We are waiting for Lilly, JNJ, and Takeda orals to replace apremilast.
Click to expand...
Man you Amgen cucks do nothing all day but troll other boards.
 



anonymous said:
Zero data, anywhere, that it's "safer" than a JAK. Show me the head to head trials?

That's why you guys lost it pre-launch when your "medical" people were running around saying it's safer than apremilast. It might not have the nuisance side effects, but it is no safer.

Face it, you guys blew it. We are waiting for Lilly, JNJ, and Takeda orals to replace apremilast.
Click to expand...
I can’t believe we aren’t getting laid off.
 



anonymous said:
Zero data, anywhere, that it's "safer" than a JAK. Show me the head to head trials?

That's why you guys lost it pre-launch when your "medical" people were running around saying it's safer than apremilast. It might not have the nuisance side effects, but it is no safer.

Face it, you guys blew it. We are waiting for Lilly, JNJ, and Takeda orals to replace apremilast.
Click to expand...
Love,
your Amgen rep near you
 



Top Bottom
Back
Quote